Asterias Biotherapeutics Inc (NYSEMKT:AST) COO Katharine E. Spink sold 4,781 shares of the firm’s stock in a transaction on Thursday, October 6th. The shares were sold at an average price of $4.11, for a total transaction of $19,649.91. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Katharine E. Spink also recently made the following trade(s):

  • On Friday, September 9th, Katharine E. Spink sold 19,336 shares of Asterias Biotherapeutics stock. The shares were sold at an average price of $3.52, for a total transaction of $68,062.72.

Asterias Biotherapeutics Inc (NYSEMKT:AST) opened at 3.88 on Wednesday. The stock’s market capitalization is $176.22 million. Asterias Biotherapeutics Inc has a 1-year low of $2.30 and a 1-year high of $5.75. The company’s 50 day moving average is $3.75 and its 200-day moving average is $3.50.

Asterias Biotherapeutics (NYSEMKT:AST) last posted its earnings results on Monday, August 15th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.07. The firm earned $1.53 million during the quarter, compared to analyst estimates of $1.14 million. Analysts forecast that Asterias Biotherapeutics Inc will post ($0.73) earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for Asterias Biotherapeutics (NYSEMKT:AST)

A number of equities analysts have commented on the stock. Zacks Investment Research raised shares of Asterias Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, July 19th. HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Asterias Biotherapeutics in a research note on Sunday, September 11th. Finally, FBR & Co reissued a “buy” rating on shares of Asterias Biotherapeutics in a research note on Wednesday, August 31st. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Asterias Biotherapeutics presently has a consensus rating of “Buy” and an average target price of $7.75.

Several institutional investors have recently bought and sold shares of AST. BlackRock Fund Advisors boosted its position in Asterias Biotherapeutics by 114.4% in the second quarter. BlackRock Fund Advisors now owns 586,720 shares of the company’s stock valued at $1,408,000 after buying an additional 313,067 shares in the last quarter. Sabby Management LLC bought a new position in Asterias Biotherapeutics during the second quarter worth $741,000. State Street Corp boosted its position in Asterias Biotherapeutics by 5.5% in the first quarter. State Street Corp now owns 96,218 shares of the company’s stock worth $452,000 after buying an additional 5,000 shares in the last quarter. BlackRock Investment Management LLC boosted its position in Asterias Biotherapeutics by 100.7% in the second quarter. BlackRock Investment Management LLC now owns 73,307 shares of the company’s stock worth $176,000 after buying an additional 36,782 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its position in Asterias Biotherapeutics by 55.7% in the second quarter. Bank of New York Mellon Corp now owns 54,406 shares of the company’s stock worth $131,000 after buying an additional 19,469 shares in the last quarter.

About Asterias Biotherapeutics

Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.

Receive News & Stock Ratings for Asterias Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics Inc and related stocks with our FREE daily email newsletter.